Identification of tumor antigens in ovarian cancers using local and circulating tumor‐specific antibodies
journal contributionposted on 2022-03-21, 23:23 authored by Jessica da Gama DuarteJessica da Gama Duarte, Luke Quigley, AR Young, M Hayashi, M Miyazawa, A Lopata, N Mancuso, M Mikami, Andreas BehrenAndreas Behren, E Meeusen
Ovarian cancers include several disease subtypes and patients often present with advanced metastatic disease and a poor prognosis. New biomarkers for early diagnosis and targeted therapy are, therefore, urgently required. This study uses antibodies produced locally in tumor-draining lymph nodes (ASC probes) of individual ovarian cancer patients to screen two separate protein microarray platforms and identify cognate tumor antigens. The resulting antigen profiles were unique for each individual cancer patient and were used to generate a 50‐antigen custom mi-croarray. Serum from a separate cohort of ovarian cancer patients encompassing four disease sub-types was screened on the custom array and we identified 28.8% of all ovarian cancers, with a higher sensitivity for mucinous (50.0%) and serous (40.0%) subtypes. Combining local and circulating antibodies with high‐density protein microarrays can identify novel, patient‐specific tumor‐associated antigens that may have diagnostic, prognostic or therapeutic uses in ovarian cancer.